This inhibition enhances the ability of tumor cells to evade the immune system, leading to a sudden decline in the clinical efficacy of trastuzumab in patients with metastatic human epidermal growth factor receptor 2 (HER2) breast cancer (Fig. 2E). This evidence concerns the gene ERBB2 and breast carcinoma.